Educate that PCSK9 Inhibitors Haven't Been Proven to Reduce CV Outcomes

You'll hear buzz about "PCSK9 inhibitors" for high cholesterol, Praluent (PRAL-you-ent, alirocumab) and Repatha (rih-PATH-ah, evolocumab).

These monoclonal antibodies will be the first biologics injected subcutaneously once or twice a month for high LDL cholesterol.

They prevent the protein PCSK9...proprotein convertase subtilisin kexin type 9...from binding and degrading liver LDL receptors. This leads to more LDL receptors...and more LDL cholesterol clearing from the blood.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals